Cardium’s clearly laid out strategy is to build a portfolio of medical product candidates at various stages of development, commercializing them in a timely manner. So far, this is exactly what they’ve managed to do as they move forward with products at different levels of development and commercialization.
Their major product candidate Generx has been undergoing clinical study at key medical centers in Russia, all in connection with commercialization plans covering the marketing and sale of Generx in the Russian Federation (and CIS). Generx, a DNA-based angiogenic growth factor therapeutic, offers a uniquely easy to use and cost effective treatment for people with advanced coronary artery disease. Unlike other non-invasive heart disease treatments, Generx actually stimulates the growth of blood vessels around the heart, rather than simply masking the pain. They are also seeking clinical development and commercialization partners for Generx in other countries, such as India, China, and Brazil, where the need for simpler but cost effective treatments is greatest.
At the same time, Cardium has been securing commercialization partners for the marketing and sale of their already FDA-cleared advanced wound care product, Excellagen. The company recently announced a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, a big step considering that Academy is a key supplier to the government’s massive Veterans Administration healthcare system and military hospitals. Cardium is also developing additional related tissue regeneration product extensions, to include small molecule drugs, peptides, stem cells, conditioned cell media, DNA-based biologic products, and Excellagen-based antimicrobials.
As far as products already holding a well-established place in the market, Cardium’s subsidiary To Go Brands has a wide portfolio of healthy-lifestyle products, already proven in the marketplace and generating dependable revenue. To Go Brands sells 100%-natural nutraceutical powder mixes, supplements, and chews, designed for convenient use by a growing market of health-conscious consumers.
For additional information, visit www.CardiumTHX.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
